Peptide (Peptide API/Intermediate/CDMO) Project多肽（多肽原料药/中间体/CDMO）项目

In terms of customized innovative drug cooperation, our company focuses on building a "turnkey" service platform for a peptide drug factory targeting the "global blockbuster—the king of hypoglycemic and weight-loss drugs," integrating the three-dimensional advantages of "equipment, process, and system." We provide end-to-end CDMO solutions for peptide active pharmaceutical ingredients, ensuring full-chain control from molecular structure to market approval, accelerating transformation, and making peptide drug development as simple and reliable as "building with LEGO." Currently, active engagements are underway in Latin America, the Middle East, Central Asia, and Southeast Asia, which is expected to become a new growth driver for technological global outreach and mutual benefit. Our company has already reached a preliminary cooperation agreement with relevant ministries and a state-owned pharmaceutical enterprise in a Central Asian country, planning to produce generic semaglutide and some small nucleic acid drugs locally. The implementation of this project still requires some funding.

创新药定制合作方面，我司重点打造“全球百亿销量－降糖、减重药王”的多肽类药物工厂“交钥匙”服务平台，集聚“设备－工艺－体系”三维融合优势，提供端到端的多肽原料药CDMO解决方案，从分子结构到上市许可，全链掌控，加速转化，让多肽药物开发像“拼乐高”一样简单可靠。目前拉美、中东、中亚、东南亚等地均在积极对接中，相信将成为科技出海，全球共赢的新增长点，目前我司已经在中亚某国相关部委和国药企业达成初步合作协议，计划在中亚生产生产仿制药司美格鲁肽及部分小核酸。该项目实施过程中还需要部分资金。